WHAT IS CLAIMED:

1. A compound of formulas I and II:



and



(I) (II)

wherein:

X is hydrogen, an alkali metal or a basic amine moiety

R_1 is C_1-C_8 alkyl, C_3-C_6 cycloalkyl, -CH_2-C_3-C_6 cycloalkyl, pyridinyl, -CH_2-pyridinyl, phenyl or benzyl, wherein the rings of the cycloalkyl, pyridinyl, phenyl and benzyl groups may be optionally substituted by from 1 to 3 groups selected from halogen, C_1-C_6 alkyl, C_1-C_6 perfluoroalkyl, -O-C_1-C_6 perfluoroalkyl, C_1-C_6 alkoxy, -OH, -NH_2, or -NO_2;

R_2 is hydrogen, halogen, C_1-C_6 alkyl, C_1-C_3 perfluoroalkyl, C_1-C_6 alkoxy, C_3-C_6 cycloalkyl, -CH_2-C_3-C_6 cycloalkyl, hydroxy, -NH_2, or -NO_2;

R_3 is hydrogen, halogen, C_1-C_6 alkyl, C_1-C_3 perfluoroalkyl, C_1-C_6 alkoxy, C_3-C_6 cycloalkyl, -CH_2-C_3-C_6 cycloalkyl, hydroxy, -NH_2, -NO_2, phenyl, benzyl, benzyloxy, pyridinyl, or -CH_2-pyridinyl, wherein the rings of these groups may be optionally substituted by from 1 to 3 groups selected from phenyl, halogen, C_1-C_6 alkyl, C_1-C_6 perfluoroalkyl, -O-C_1-C_6 perfluoroalkyl, C_1-C_6 alkoxy, -OH, -NH_2, or -NO_2; or a pharmaceutically acceptable salt or ester form thereof.

2. A compound of formula III:



(III)

wherein:

R_1 is C_1-C_8 alkyl, C_3-C_6 cycloalkyl, -CH_2-C_3-C_6 cycloalkyl, pyridinyl, -CH_2-pyridinyl, phenyl or benzyl, wherein the rings of the cycloalkyl, pyridinyl, phenyl and benzyl groups may be optionally substituted by from 1 to 3 groups selected from halogen, C_1-C_6 alkyl, C_1-C_6 perfluoroalkyl, -O-C_1-C_6 perfluoroalkyl, C_1-C_6 alkoxy, -OH, -NH_2, or -NO_2;

R_2 is hydrogen, halogen, C_1-C_6 alkyl, C_1-C_3 perfluoroalkyl, C_1-C_6 alkoxy, C_3-C_6 cycloalkyl, -CH_2-C_3-C_6 cycloalkyl, -NH_2, or -NO_2;

R_3 is hydrogen, halogen, C_1-C_6 alkyl, C_1-C_3 perfluoroalkyl, C_1-C_6 alkoxy, C_3-C_6 cycloalkyl, -CH_2-C_3-C_6 cycloalkyl, hydroxy, -NH_2, -NO_2, phenyl, benzyl, benzyloxy, pyridinyl, or -CH_2-pyridinyl, wherein the rings of these groups may be optionally substituted by from 1 to 3 groups selected from halogen, C_1-C_6 alkyl, C_1-C_6 perfluoroalkyl, -O-C_1-C_6 perfluoroalkyl, C_1-C_6 alkoxy, -OH, -NH_2, or -NO_2; or a pharmaceutically acceptable salt or ester form thereof.

3. A compound of formula (IV)



(IV)

wherein:

R_1 is C_1-C_8 alkyl, C_3-C_6 cycloalkyl, -CH_2-C_3-C_6 cycloalkyl, pyridinyl, -CH_2-pyridinyl, phenyl or benzyl, wherein the rings of the cycloalkyl, pyridinyl, phenyl and benzyl groups may be optionally substituted by from 1 to 3 groups selected from halogen, C_1-C_6 alkyl, C_1-C_6 perfluoroalkyl, -O-C_1-C_6 perfluoroalkyl, C_1-C_6 alkoxy, -OH, -NH_2, or -NO_2;

R_2 is hydrogen, halogen, C_1-C_6 alkyl, C_1-C_3 perfluoroalkyl, C_1-C_6 alkoxy, C_3-C_6 cycloalkyl, -CH_2-C_3-C_6 cycloalkyl, -NH_2, or -NO_2;

R_3 phenyl, benzyl, benzyloxy, pyridinyl, or -CH_2-pyridinyl, with the rings of these groups being optionally substituted by from 1 to 3 groups selected from halogen, C_1-C_3 alkyl, C_1-C_3 perfluoroalkyl, -O-C_1-C_3 perfluoroalkyl, C_1-C_3 alkoxy, -OH, -NH_2, or -NO_2; or a pharmaceutically acceptable salt or ester form thereof.

4. A compound of formula (V):



(V)

wherein:

R_1 is C_1-C_8 alkyl, preferably C_1-C_6 alkyl, C_3-C_6 cycloalkyl, -CH_2-C_3-C_6 cycloalkyl, or benzyl, wherein the rings of the cycloalkyl and benzyl groups may be optionally substituted by from 1 to 3 groups selected from halogen, C_1-C_6 alkyl, C_1-C_6 perfluoroalkyl, -O-C_1-C_6 perfluoroalkyl, C_1-C_6 alkoxy, -OH, -NH_2, or -NO_2;

R_2 is hydrogen, halogen, C_1-C_6 alkyl, C_1-C_3 perfluoroalkyl, preferably –CF_3, C_1-C_6 alkoxy, C_3-C_6 cycloalkyl, -CH_2-C_3-C_6 cycloalkyl, hydroxy, -NH_2, or -NO_2;

R_4, R_5 and R_6 are each independently hydrogen, phenyl, halogen, C_1-C_3 alkyl, C_1-C_3 perfluoroalkyl, -O-C_1-C_3 perfluoroalkyl, C_1-C_3 alkoxy, -OH, $-NH_2$, or $-NO_2$; or a pharmaceutically acceptable salt or ester form thereof.

5. A compound of formula VI:



(VI)

wherein:

R_1 is C_1-C_8 alkyl, C_3-C_6 cycloalkyl, -CH_2-C_3-C_6 cycloalkyl, or benzyl, wherein the rings of the cycloalkyl and benzyl groups may be optionally substituted by from 1 to 3 groups selected from halogen, C_1-C_6 alkyl, C_1-C_6 perfluoroalkyl, preferably $-CF_3$, -O-C_1-C_6 perfluoroalkyl, preferably $-O-CF_3$, C_1-C_6 alkoxy, -OH, $-NH_2$, or $-NO_2$;

R_2 is hydrogen, halogen, C_1-C_6 alkyl, C_1-C_3 perfluoroalkyl, preferably $-CF_3$, C_1-C_6 alkoxy, C_3-C_6 cycloalkyl, -CH_2-C_3-C_6 cycloalkyl, hydroxy, $-NH_2$, or $-NO_2$; and

R_4, R_5 and R_6 are each independently hydrogen, halogen, C_1-C_3 alkyl, C_1-C_3 perfluoroalkyl, preferably $-CF_3$, -O-C_1-C_3 perfluoroalkyl, preferably $-O-CF_3$, C_1-C_3 alkoxy, -OH, $-NH_2$, or $-NO_2$; or a pharmaceutically acceptable salt or ester form thereof.

6. The compound of Claim 1 which is 9-(4-Methylbenzyl)-6-[4-(trifluoromethoxy)phenyl]-1,9-dihydropyrano[3,4-*b*]indole-3,4-dione or a pharmaceutically acceptable salt or ester form thereof.

7. The compound of Claim 1 which is 9-Benzyl-6-[4-(trifluoromethoxy)phenyl]-1,9-dihydropyrano[3,4-*b*]indole-3,4-dione or a pharmaceutically acceptable salt or ester form thereof.

8. The compound of claim 1 which is 9-(4-Methylbenzyl)-6-(3-Methylphenyl)-1,9-dihydropyrano[3,4-b]indole-3,3-dione or a pharmaceutically acceptable salt or ester form thereof.

9. The compound of claim 1 which is 9-(4-tert-butylbenzyl)-6-(3-Methylphenyl)-1,9-dihydropyrano[3,4-b] indole-3,4-dione or a pharmaceutically acceptable salt or ester form thereof.

10. The compound of claim 1 which is 6-(Benzyloxy)-9-(4-methylbenzyl)-1,9-dihydropyrano[3,4-b]indole-3,4-dione or a pharmaceutically acceptable salt or ester form thereof.

11. The compound of claim 1 which is 6-(Benzyloxy)-1,9-dihydropyrano[3,4-b]indole-3,4-dione or a pharmaceutically acceptable salt or ester form thereof.

12. The compound of claim 1 which is 6-(Benzyloxy)-9-(4-tertbutylbenzyl)-1,9-dihydropyrano[3,4-b]indole-3,4-dione or a pharmaceutically acceptable salt or ester form thereof.

13. The compound of claim 1 which is 9-(4-tertbutybenzyl)-6-hydroxy-1,9-dihydropyrano[3,4-b]indole-3,4-dione or a pharmaceutically acceptable salt or ester form thereof.

14. The compound of claim 1 which is 9-benzyl-6-(4-chlorophenyl)-1,9-dihydropyrano[3,4-b]indole-3,4-dione or a pharmaceutically acceptable salt or ester form thereof.

15. The compound of claim 1 which is [1-benzyl-5-(4-chlorophenyl)-2-(hydroxymethyl)-1H-indole-2-yl] (oxo)acetic acid, or a pharmaceutically acceptable salt or ester form thereof.

16. The compound of claim 1 which is 9-benzyl-6-(3-Methylphenyl)-1,9-dihydropyrano[3,4-b]indole-3,4-dione or a pharmaceutically acceptable salt or ester form thereof.

17. The compound of claim 1 which is 9-benzyl-6-(1-1-bi-phenyl-4-yl)-1,9-dihydropyrano[3,4-b]indole-3,4-dione or a pharmaceutically acceptable salt or ester form thereof.

18. The compound of claim 1 which is [1-benzyl-5-(1,1-biphenyl-4-yl)-2-(hydroxymethyl)-1H-indole-3-yl] (oxo)acetic acid, or a pharmaceutically acceptable salt or ester form thereof.

19. A method of inhibiting plasminogen activator inhibitor in a mammal comprising administering to a mammal in need thereof a therapeutically effective amount of a compound of claim 1

20. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutical carrier.

21. A method for treatment of thrombosis or fibrinolytic impairment in a mammal, the method comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of Claim 1.

22. A method of Claim 21 wherein the thrombosis or fibrinolytic impairment is associated with formation of atherosclerotic plaques, venous and arterial thrombosis, myocardial ischemia, atrial fibrillation, deep vein thrombosis, coagulation syndromes, pulmonary fibrosis, cerebral thrombosis, thromboembolic complications of surgery or peripheral arterial occlusion.

23. A method for the treatment of peripheral arterial disease in a mammal, comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of Claim 1.

24. A method for the treatment of stroke associated with or resulting from atrial fibrillation in a mammal, comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of Claim 1.

25. A method for the treatment of deep vein thrombosis in a mammal, comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of Claim 1.

26. A method for the treatment of myocardial ischemia in a mammal, comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of Claim 1.

27. A method for the treatment of a cardiovascular disease caused by noninsulin dependent diabetes mellitus in a mammal, comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of Claim 1.

28. A method for the treatment of the formation of atherosclerotic plaques in a mammal, comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of Claim 1.

29. A method for the treatment of chronic obstructive pulmonary disease in a mammal, comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of Claim 1.

30. A method for the treatment of renal fibrosis in a mammal, comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of Claim 1.

31. A method for the treatment of polycystic ovary syndrome in a mammal, comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of Claim 1.

32. A method for the treatment of Alzheimer's disease in a mammal, comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of Claim1.

33. A method for the treatment of cancer in a mammal, comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of Claim 1.